2021
Abstract CT129: ARC-3: Updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients
Cecchini M, Quah C, Liu S, Woloski R, Udyavar A, Giannakis M. Abstract CT129: ARC-3: Updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients. Cancer Research 2021, 81: ct129-ct129. DOI: 10.1158/1538-7445.am2021-ct129.Peer-Reviewed Original ResearchModified FOLFOX-6Metastatic colorectal cancerFOLFOX-6American Association for Cancer Research annual meetingsColorectal cancerAnti-tumor immune responseAssociated with disease controlDying cancer cellsMCRC ptsAdenosine receptor blockadeOpen-label studyRelease of ATPAntagonists of A2ARMedian PFSPretreated ptsReceptor blockadeEligible ptsOrally onceExtracellular adenosineA2B receptorsImmune cellsChemotherapeutic agentsTherapeutic efficacyClinical activityImmune response
2020
Abstract CT246: Consortium-IO: A safety and efficacy study of VE800 in combination with nivolumab in previously treated patients with select advanced metastatic cancers
Davar D, Wang J, Cecchini M, Wainberg Z, Gutierrez M, Turk A, Szabady R, Norman J, Olle B, Roberts B, Bobilev D. Abstract CT246: Consortium-IO: A safety and efficacy study of VE800 in combination with nivolumab in previously treated patients with select advanced metastatic cancers. Cancer Research 2020, 80: ct246-ct246. DOI: 10.1158/1538-7445.am2020-ct246.Peer-Reviewed Original ResearchPD-1 blockadeResponse to PD-1 blockadeDisease control rateDose-limiting toxicityProgression-free survivalDuration of responseOverall survivalTreated patientsResistance to PD-1 blockadeCD8+ T cell infiltrationCancer patientsCD103+ dendritic cellsCourses of oral vancomycinClinical activitySimon 2-stage designMajor histocompatibilityT cell infiltrationMicrosatellite-stablePhase I studyEfficacy studiesAmerican Association for Cancer ResearchMultiple tumor modelsAdvanced metastatic cancerSingle dose levelAnti-tumor activity